Excision's cutting edge CRISPR gene therapy platform is built on technology licensed from the Doudna Lab at UC Berkeley and the Khalili Lab at Temple University.
We are the first company to remove HIV genomes from animals and generate functional cures for HIV.
Excision products require one-time gene edit to remove the viral genome permanently
“I am optimistic that Excision’s technology and approach using CRISPR could potentially cure infectious diseases and bring much needed therapies to those in need around the world.”
Biopharma tackles COVID-19, HIV and other viruses with gene and cell therapies
Excision Bio Announces Data Presentation at CROI from IND-Enabling Non-Human Primate Studies of EBT-001, Supporting a CRISPR Gene Editing Technology for HIV Elimination
PRESS RELEASE
MAR 2020
Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice
